EUVIMEDEUVIMED entdecken
Crossref

Design, synthesis and anti-Parkinson's disease bioactivity evaluation of isoquinoline derivatives as potent IDO1/TDO dual inhibitors

Zhongzhen Yang, Zhiqian Lin, Chunyan Yang, Runxin Lu, Yong Wu

Bioorganic & Medicinal Chemistry Letters · 2026

DOI: 10.1016/j.bmcl.2026.130596 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2026. Verfasst von Zhongzhen Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, West China Hospital, Sichuan University, Chengdu 610041, PR China. Hauptthemen laut MEDLINE: Indoleamine-Pyrrole 2,3,-Dioxygenase, Isoquinolines, Drug Design, Enzyme Inhibitors. Die Arbeit nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) are potential targets for the development of PD according to current research; nevertheless, reports on dual hIDO1/hTDO inhibitors against PD are still lacking. In this study, a series of isoquinoline derivatives were designed, synthesized, and evaluated as novel IDO1/TDO dual inhibitors. Among them, Y-13 showed potent inhibitory activities against both IDO1 (IC50 = 2.87 ± 0.93 μM) and TDO (IC50 = 0.08 ± 0.01 μM). The neuroprotective efficiency of Y-13 against PD was explored in vitro and in vivo. It was found that Y-13 could protect BV2 cells from neuroinflammation by inhibiting NO and ROS generation and improve cognitive function, learning ability, and motor performance in a MPTP-induced PD rat model. In general, our study has demonstrated that Y-13 has significant efficacy against PD in vitro and in vivo experiments, which can provide guidance for the development of IDO1/TDO dual inhibitors to treat PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Indoleamine-Pyrrole 2,3,-DioxygenaseIsoquinolinesDrug DesignEnzyme InhibitorsTryptophan OxygenaseParkinson DiseaseNeuroprotective AgentsAnimalsHumansStructure-Activity RelationshipRatsMolecular StructureDose-Response Relationship, DrugMice

Stichwörter der Autor:innen

Anti-inflammatory effectsIsoquinoline derivativesNeuroprotective effectsParkinson's diseaseTryptophan-kynurenine pathway

Substanzen

Indoleamine-Pyrrole 2,3,-DioxygenaseIsoquinolinesEnzyme InhibitorsTryptophan OxygenaseNeuroprotective AgentsIDO1 protein, human

Autor:innen und Institutionen

  • Department of Pharmacy, West China Hospital, Sichuan University, Chengdu 610041, PR China.
  • Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial T…
  • Department of Pharmacy/Evidence-Based Pharmacy Center, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Children's Medicine Key Laboratory of Sichuan Province, NMPA Key Laboratory for Technica…

Zitieren

APA

Yang, Z., Lin, Z., Yang, C., Lu, R., & Wu, Y. (2026). Design, synthesis and anti-Parkinson's disease bioactivity evaluation of isoquinoline derivatives as potent IDO1/TDO dual inhibitors. Bioorganic & Medicinal Chemistry Letters. https://doi.org/10.1016/j.bmcl.2026.130596

Vancouver

Yang Z, Lin Z, Yang C, Lu R, Wu Y. Design, synthesis and anti-Parkinson's disease bioactivity evaluation of isoquinoline derivatives as potent IDO1/TDO dual inhibitors. Bioorganic & Medicinal Chemistry Letters. 2026. doi:10.1016/j.bmcl.2026.130596

BibTeX
@article{Yang2026,
  author = {Yang, Zhongzhen and Lin, Zhiqian and Yang, Chunyan and Lu, Runxin and Wu, Yong},
  title = {Design, synthesis and anti-Parkinson's disease bioactivity evaluation of isoquinoline derivatives as potent IDO1/TDO dual inhibitors},
  journal = {Bioorganic & Medicinal Chemistry Letters},
  year = {2026},
  doi = {10.1016/j.bmcl.2026.130596}
}
Kostenlos starten →